GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » 3-Year EBITDA Growth Rate

BCRX (BioCryst Pharmaceuticals) 3-Year EBITDA Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals 3-Year EBITDA Growth Rate?

BioCryst Pharmaceuticals's EBITDA per Share for the three months ended in Dec. 2024 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioCryst Pharmaceuticals was 41.90% per year. The lowest was -63.70% per year. And the median was 2.40% per year.

Competitive Comparison of BioCryst Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCryst Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.


;
;

BioCryst Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

BioCryst Pharmaceuticals  (NAS:BCRX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BioCryst Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
KNSA DVAX SUPN ANIP NDOI AMPH PCRX BGM NIKA COLL ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
BO1:Germany BO1:Germany
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
Website
https://www.biocryst.com
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Theresa Heggie director 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703
Alan G Levin director ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244